Literature DB >> 17186568

The pharmacological properties of anisodamine.

Jay M Poupko1, Steven I Baskin, Eric Moore.   

Abstract

Anisodamine is a naturally occurring atropine derivative that has been isolated, synthesized and characterized by scientists in the People's Republic of China. Like atropine and scopolamine, anisodamine is a non-specific cholinergic antagonist exhibiting the usual spectrum of pharmacological effects of this drug class. It appears to be less potent and less toxic than atropine and displays less CNS toxicity than scopolamine. Anisodamine has been shown to interact with and disrupt liposome structure which may reflect its effects on cellular membranes. Experimental evidence implicates anisodamine as an anti-oxidant that may protect against free radical-induced cellular damage. Its cardiovascular properties include depression of cardiac conduction and the ability to protect against arrhythmia induced by various agents. Anisodamine is a relatively weak alpha(1) adrenergic antagonist which may explain its vasodilating activity. Its anti-thrombotic activity may be a result of inhibition of thromboxane synthesis. The T(1/2) of anisodamine in humans is about 2-3 h. Numerous therapeutic uses of anisodamine have been proposed including treatment of septic shock, various circulatory disorders, organophosphorus (OP) poisoning, migraine, gastric ulcers, gastrointestinal colic, acute glomerular nephritis, eclampsia, respiratory diseases, rheumatoid arthritis, obstructive jaundice, opiate addiction, snake bite and radiation damage protection. The primary therapeutic use of anisodamine has been for the treatment of septic shock. Several mechanisms have been proposed to explain its beneficial effect though most mechanisms are based upon the assumption that anisodamine ultimately acts by an improvement of blood flow in the microcirculation. Preliminary studies suggest another important therapeutic use of anisodamine is for the treatment of OP poisoning. Additional research is needed to delineate further the clinical usefulness of anisodamine relative to other anti-muscarinic drugs such as atropine and scopolamine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17186568     DOI: 10.1002/jat.1154

Source DB:  PubMed          Journal:  J Appl Toxicol        ISSN: 0260-437X            Impact factor:   3.446


  30 in total

1.  Peripheral cholinoceptor antagonist anisodamine counteracts cholinergic adverse effects and facilitates cognitive amelioration of rivastigmine.

Authors:  Wei-Wei Zhang; Zu-Peng Xu; Yong-Yao Cui; Hao Wang; Ming-Ke Song; Juan Li; Bi-Yun Shao; Zheng Xia; Hong-Zhuan Chen
Journal:  J Neural Transm (Vienna)       Date:  2009-09-12       Impact factor: 3.575

2.  The value of synchro-cystourethrometry for evaluating the relationship between urethral instability and overactive bladder.

Authors:  Chaoyang Hua; Yibo Wen; Yan Zhang; Quande Feng; Xiangfei He; Yunlong Li; Junwei Wu; Jinjin Feng; Stuart B Bauer; Jianguo Wen
Journal:  Int Urol Nephrol       Date:  2018-01-03       Impact factor: 2.370

Review 3.  Possible role for anisodamine in organophosphate poisoning.

Authors:  Arik Eisenkraft; Avshalom Falk
Journal:  Br J Pharmacol       Date:  2016-04-22       Impact factor: 8.739

4.  Anisodamine accelerates spontaneous passage of single symptomatic bile duct stones ≤ 10 mm.

Authors:  Jun Gao; Xue-Mei Ding; Shan Ke; Yi-Ming Zhou; Xiao-Jun Qian; Rui-Liang Ma; Chun-Min Ning; Zong-Hai Xin; Wen-Bing Sun
Journal:  World J Gastroenterol       Date:  2013-10-21       Impact factor: 5.742

5.  Comparative study on pharmacokinetics of a series of anticholinergics, atropine, anisodamine, anisodine, scopolamine and tiotropium in rats.

Authors:  Fengjie Tian; Cuiyun Li; Xin Wang; Shuangxia Ren; Ning Li; Qi Liu; Sufeng Zhou; Yang Lu; Di Zhao; Xijing Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-04-20       Impact factor: 2.441

6.  Effectiveness of anisodamine for the treatment of critically ill patients with septic shock (ACIdoSIS study): study protocol for randomized controlled trial.

Authors:  Zhongheng Zhang; Jiancang Zhou; You Shang; Xin'an Wang; Rui Yin; Zhenhua Zhu; Wensen Chen; Xin Tian; Yuetian Yu; Xiangrong Zuo; Kun Chen; Xuqing Ji; Hongying Ni
Journal:  Ann Transl Med       Date:  2015-10

7.  Combined administration of anisodamine and neostigmine produces anti-shock effects: involvement of α7 nicotinic acetylcholine receptors.

Authors:  Li Sun; Gu-fang Zhang; Xin Zhang; Qing Liu; Jian-guo Liu; Ding-feng Su; Chong Liu
Journal:  Acta Pharmacol Sin       Date:  2012-05-14       Impact factor: 6.150

8.  Effects of early administration of a novel anticholinergic drug on acute respiratory distress syndrome induced by sepsis.

Authors:  Hao Li; Zhaoxin Qian; Jianmin Li; Xiaotong Han; Min Liu
Journal:  Med Sci Monit       Date:  2011-11

9.  Beneficial effects of anisodamine in shock involved cholinergic anti-inflammatory pathway.

Authors:  Ting Zhao; Dong-Jie Li; Chong Liu; Ding-Feng Su; Fu-Ming Shen
Journal:  Front Pharmacol       Date:  2011-05-02       Impact factor: 5.810

10.  New Perspectives on How to Discover Drugs from Herbal Medicines: CAM's Outstanding Contribution to Modern Therapeutics.

Authors:  Si-Yuan Pan; Shu-Feng Zhou; Si-Hua Gao; Zhi-Ling Yu; Shuo-Feng Zhang; Min-Ke Tang; Jian-Ning Sun; Dik-Lung Ma; Yi-Fan Han; Wang-Fun Fong; Kam-Ming Ko
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.